Macro Finance
Novo Plunges as Investors Seek More Robust Sales Targets
Bloomberg Markets·September 21, 2026·1 min read
Novo Nordisk shares plunged in early trading after the Danish drugmaker pledged to launch more than five blockbuster drugs and deliver over $23 billion in new sales in coming years. Investors wanted more concrete turnaround plans from CEO Mike Doustdar after losing its lead in the obesity market to Eli Lilly, according to Bloomberg's Sanne Wass.
Read at Bloomberg MarketsDaily crypto arcade
Read the news, then play it.
Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.